Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Edmondson

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|April 29, 2026
Design of Cyclic Vinyl Sulfones as WRN Covalent Inhibitors from Noncovalent BindersJustin A Caravella, Angela V Toms, Nikolay Sitnikov, et al.
Bioorganic & Medicinal Chemistry Letters|March 1, 2011
Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonistsGregori J Morriello, Harvey R Wendt, Alka Bansal, et al.
Journal of Medicinal Chemistry|June 9, 2006
(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesScott D Edmondson, Anthony Mastracchio, Robert J Mathvink, et al.
Journal of Medicinal Chemistry|January 21, 2014
Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladderChristopher R Moyes, Richard Berger, Stephen D Goble, et al.
Journal of Medicinal Chemistry|July 10, 2023
Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279Silvana Leit, Jeremy Greenwood, Samantha Carriero, et al.
Bioorganic & Medicinal Chemistry Letters|February 11, 2017
Discovery of phenyl acetamides as potent and selective GPR119 agonistsCheng Zhu, Liping Wang, Yuping Zhu, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 DiabetesLiangqin Guo, Dann L Parker, Yi Zang, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II DiabetesPing Liu, Zhiyong Hu, Byron G DuBois, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2023
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Amber Balazs, et al.
Journal of Medicinal Chemistry|December 29, 2015
Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive BladderScott D Edmondson, Cheng Zhu, Nam Fung Kar, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|April 29, 2026
Design of Cyclic Vinyl Sulfones as WRN Covalent Inhibitors from Noncovalent BindersJustin A Caravella, Angela V Toms, Nikolay Sitnikov, et al.
Bioorganic & Medicinal Chemistry Letters|March 1, 2011
Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonistsGregori J Morriello, Harvey R Wendt, Alka Bansal, et al.
Journal of Medicinal Chemistry|June 9, 2006
(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesScott D Edmondson, Anthony Mastracchio, Robert J Mathvink, et al.
Journal of Medicinal Chemistry|January 21, 2014
Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladderChristopher R Moyes, Richard Berger, Stephen D Goble, et al.
Journal of Medicinal Chemistry|July 10, 2023
Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279Silvana Leit, Jeremy Greenwood, Samantha Carriero, et al.
Bioorganic & Medicinal Chemistry Letters|February 11, 2017
Discovery of phenyl acetamides as potent and selective GPR119 agonistsCheng Zhu, Liping Wang, Yuping Zhu, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 DiabetesLiangqin Guo, Dann L Parker, Yi Zang, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II DiabetesPing Liu, Zhiyong Hu, Byron G DuBois, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2023
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Amber Balazs, et al.
Journal of Medicinal Chemistry|December 29, 2015
Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive BladderScott D Edmondson, Cheng Zhu, Nam Fung Kar, et al.
Pageof 5